///四环医药的牌面，悄悄活了。资深分析师：尧 今一家药企的重生，往往藏在最意想不到的地方。四环医药，曾是资本市场人人追捧的白马股，凭借一系列心脑血管产品站稳脚跟，巅峰市值超500亿港元，彼时同期可比肩复星医药、中国生物制药等当前医药巨头。然而，花无百日红。政策与行业的浪潮翻涌之下，曾经的王者迅速跌落神坛。而今市值缩水至100多亿，连子公司轩竹生物远超于它。业绩连亏三年，光环渐失。就在所有人...
Source Link///四环医药的牌面，悄悄活了。资深分析师：尧 今一家药企的重生，往往藏在最意想不到的地方。四环医药，曾是资本市场人人追捧的白马股，凭借一系列心脑血管产品站稳脚跟，巅峰市值超500亿港元，彼时同期可比肩复星医药、中国生物制药等当前医药巨头。然而，花无百日红。政策与行业的浪潮翻涌之下，曾经的王者迅速跌落神坛。而今市值缩水至100多亿，连子公司轩竹生物远超于它。业绩连亏三年，光环渐失。就在所有人...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.